XXXX in @entity1 who have undergone transplantation.

@entity1 @entity281 @entity6656 @entity166 @entity5638
In the early years of transplantation in Arizona, @entity6656 occurred in 7% to 9% of recipients, with a mortality rate as high as 72% in some cases. In current transplant programs, however, evolution of immunosuppression and institution of targeted prophylaxis have resulted in @entity281 rates ranging from 1% to 2%. The clinical characteristics of this @entity281 among transplant recipients range from asymptomatic to fulminant and fatal. Dissemination is common, and mortality is high (28%). Because serologic response is often absent or slow, diagnosis can be challenging and often requires invasive diagnostic procedures. Pharmacologic treatment follows the guidelines of the @entity166 Society of America, but control of @entity281 may also dictate a decrease in immunosuppressant treatment. After @entity281 is controlled, secondary azole prophylaxis is recommended to prevent relapse. @entity1 with a history of @entity6656 may undergo successful transplantation when disease is inactive and @entity5638 prophylaxis is instituted. The incidence of donor-derived @entity6656 is not known. The risk of @entity281 among transplant recipients visiting in or relocating to an endemic area is low, and routine prophylaxis for this group is not recommended.
